Trial Profile
Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Levocetirizine/montelukast (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 24 Jun 2018 Results (n=228) published in the Clinical Therapeutics.
- 22 Sep 2015 New trial record